We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Fifth Circuit’s Mifepristone Decision Undercuts Judicial Review, Says Bar Association
Fifth Circuit’s Mifepristone Decision Undercuts Judicial Review, Says Bar Association
By overriding the FDA’s scientific judgments and methodology, the Fifth Circuit second-guessed the FDA’s Congressional mandate to consider all scientific evidence in drug approval decisions, the American Bar Association (ABA) wrote in its recent amicus brief on the Supreme Court’s upcoming review of the abortion drug mifepristone.